Unveiling the immune microenvironment in sinonasal intestinal type adenocarcinoma: new arguments for immunotherapy
Abstract
Sinonasal intestinal-type adenocarcinoma (ITAC) is a rare malignancy strongly associated with occupational exposure to wood dust that shares morphological and molecular similarities with colorectal adenocarcinoma. Standard treatments offer limited benefit for advanced or recurrent disease. It is therefore necessary to develop other strategies, such as immunotherapies, which require a better understanding of the tumor immune microenvironment, are needed. In this study, we investigated the immune microenvironment of ITACs (n=59), focusing on tumor-infiltrating T lymphocytes (TILs) and macrophages, in situ using immunohistochemistry, ex vivo by multiparametric flow cytometry, as well as by transcriptomic profiling. High CD8⁺ T-cell densities were associated with significantly improved disease-free and overall survival and emerged as an independent prognostic factor. These TILs express immune checkpoints (IC), the most highly expressed being PD1, TIGIT, and TIM-3. Furthermore, TIM-3 was not only expressed by TILs but also by immunoregulatory macrophages, and may represent an important immune escape mechanism in ITACs, since TIM-3 blockade in patient-derived explants led to increased tumor cell apoptosis. Tumor cells strongly expressed CD155 (TIGIT ligand) but not PDL1 (PD1 ligand); however expressed by myeloid cells. Finally, transcriptomic analyses identified one cluster displaying features of "hot tumors" characterized by adaptive immune activation, a better prognosis, and a higher immunotherapy response score, and another cluster with features of "cold tumors". These first exploratory and descriptive findings in ITACs provide a rationale for further investigations using ex vivo and in vivo models to evaluate the therapeutic potential of immunotherapies in these rare cancers.
Related
- Orbital Apex Involvement in Sinonasal Intestinal-Type Adenocarcinoma: Impact on Distant Metastasis and Mortality.
- Editorial: Community series in unveiling the next generation of cancer immunity & immunotherapy in lung cancer, volume II
- Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy
- VDAC1 regulates disulfidptosis susceptibility and associates with the immune microenvironment via multi-omics analysis in lung adenocarcinoma
- Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
BibTeX
@article{lepine2026unveiling,
title = {{Unveiling the immune microenvironment in sinonasal intestinal type adenocarcinoma: new arguments for immunotherapy}},
author = {Charles Lépine and Cécile Deleine and Richard Danger and Laura Do Souto Ferreira and Elisabeth Nguyen and Marie-Anne Vibet and Olivier Malard and Nadine Gervois and Karine Renaudin and Anne Jarry},
journal = {OncoImmunology},
year = {2026},
month = sep,
doi = {10.1080/2162402x.2026.2725500},
url = {https://inserm.hal.science/inserm-05738729v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Unveiling the immune microenvironment in sinonasal intestinal type adenocarcinoma: new arguments for immunotherapy
AU - Charles Lépine
AU - Cécile Deleine
AU - Richard Danger
AU - Laura Do Souto Ferreira
AU - Elisabeth Nguyen
AU - Marie-Anne Vibet
AU - Olivier Malard
AU - Nadine Gervois
AU - Karine Renaudin
AU - Anne Jarry
PY - 2026
DA - 2026/09/03
JO - OncoImmunology
DO - 10.1080/2162402x.2026.2725500
UR - https://inserm.hal.science/inserm-05738729v1
AB - Sinonasal intestinal-type adenocarcinoma (ITAC) is a rare malignancy strongly associated with occupational exposure to wood dust that shares morphological and molecular similarities with colorectal adenocarcinoma. Standard treatments offer limited benefit for advanced or recurrent disease. It is therefore necessary to develop other strategies, such as immunotherapies, which require a better understanding of the tumor immune microenvironment, are needed. In this study, we investigated the immune microenvironment of ITACs (n=59), focusing on tumor-infiltrating T lymphocytes (TILs) and macrophages, in situ using immunohistochemistry, ex vivo by multiparametric flow cytometry, as well as by transcriptomic profiling. High CD8⁺ T-cell densities were associated with significantly improved disease-free and overall survival and emerged as an independent prognostic factor. These TILs express immune checkpoints (IC), the most highly expressed being PD1, TIGIT, and TIM-3. Furthermore, TIM-3 was not only expressed by TILs but also by immunoregulatory macrophages, and may represent an important immune escape mechanism in ITACs, since TIM-3 blockade in patient-derived explants led to increased tumor cell apoptosis. Tumor cells strongly expressed CD155 (TIGIT ligand) but not PDL1 (PD1 ligand); however expressed by myeloid cells. Finally, transcriptomic analyses identified one cluster displaying features of "hot tumors" characterized by adaptive immune activation, a better prognosis, and a higher immunotherapy response score, and another cluster with features of "cold tumors". These first exploratory and descriptive findings in ITACs provide a rationale for further investigations using ex vivo and in vivo models to evaluate the therapeutic potential of immunotherapies in these rare cancers.
SN - 2162-4011
SN - 2162-402X
ER -